Nature Reviews Drug Discovery

For readers interested in novel cancer drugs, this Review in the November issue discusses therapeutic strategies targeting cyclin-dependent kinases that regulate RNA polymerase II-mediated transcription
nature.com/articles/s4157…
rdcu.be/e39dVNda3aLa

For readers interested in strategies in the design of kinase modulators, here's a comprehensive recent review nature.com/articles/s4157…
rdcu.be/7nDDFUkn4W9a

Our latest research highlight covers a paper in Nature on the systematic design of bitopic kinase inhibitors nature.com/articles/d4157…

Checkpoint inhibitor combinations: the trial-to-approval gap
nature.com/articles/d4157…

This article analyses trends in checkpoint inhibitor trials and FDA approvals, highlighting the rapid growth of combination regimens and the gap between trial activity and regulatory approvals

FDA approves plasmid DNA-based immunotherapy for rare viral disease nature.com/platform/rh/pr…

Inovio's doruxapapogene ralaplasmid and lalikinogene sifuplasmid for recurrent respiratory papillomatosis caused by human papillomavirus is the first plasmid DNA-based immunotherapy